塞马鲁肽在肥胖症治疗中对心血管的影响:重新定义心血管健康策略。

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Heart International Pub Date : 2024-05-22 eCollection Date: 2024-01-01 DOI:10.17925/HI.2024.18.1.1
Aditya John Binu, Nitin Kapoor
{"title":"塞马鲁肽在肥胖症治疗中对心血管的影响:重新定义心血管健康策略。","authors":"Aditya John Binu, Nitin Kapoor","doi":"10.17925/HI.2024.18.1.1","DOIUrl":null,"url":null,"abstract":"<p><p>Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"18 1","pages":"3-4"},"PeriodicalIF":1.9000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239134/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.\",\"authors\":\"Aditya John Binu, Nitin Kapoor\",\"doi\":\"10.17925/HI.2024.18.1.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.</p>\",\"PeriodicalId\":12836,\"journal\":{\"name\":\"Heart International\",\"volume\":\"18 1\",\"pages\":\"3-4\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239134/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/HI.2024.18.1.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2024.18.1.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

塞马鲁肽是一种胰高血糖素样肽 1 受体激动剂,在减轻体重和控制血糖方面发挥着重要作用。来自近期试验(SUSTAIN-6、SELECT 和 STEP HF)的越来越多的证据显示,无论是糖尿病患者还是非糖尿病患者,以及肥胖或超重患者,服用塞马鲁肽对心血管都有显著的益处。在将舍马鲁肽纳入越来越多的治疗和预防心脏疾病的指导性医疗疗法之前,有必要在更多样化的患者人群中开展更多研究并进行安全性评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.

Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Heart International
Heart International Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
9
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信